Novel Molecular Mechanisms Promote GPCR-Induced Bronchodilation in Asthma

新型分子机制促进 GPCR 诱导的哮喘支气管扩张

基本信息

项目摘要

Project Summary Our renewal of this interdisciplinary PPG remains focused on the theme of novel molecular mechanisms to inhibit human airway smooth muscle (HASM) contraction and promote bronchodilation within the context of airway inflammation and asthma. The principal hypothesis states that G protein coupled receptor (GPCR) desensitization and unbiased signaling limits the efficacy of conventional bronchodilators, such that targeting desensitization mechanisms, promoting biased agonism, circumventing mechanisms of ASM hypercontractility/airway hyperresponsiveness (AHR), or engaging novel bronchorelaxant mechanisms in HASM will provide superior therapy for asthma. Each Project addresses this hypothesis by either: 1) optimizing pro- relaxant signaling abilities of one of 3 different GPCRs using strategies rooted in cutting edge biophysical or pharmacological approaches; or 2) establishing novel intracellular targets mediating inflammation-driven AHR and increased GPCR pro-contractile signaling. Project 1 will establish the mechanisms by which TGF-β1 modulates excitation-contraction (EC) coupling of HASM and thereby identify novel therapeutic targets linked to both AHR and increased GPCR-mediated contraction. Project 2 will advance the recent discovery of bitter taste receptors (TAS2R) as novel bronchodilators clarifying the role of TAS2R subtypes in HASM, their mode of regulation and means to improve their efficacy through biased agonism. Project 3 will characterize the molecular basis of β2AR biased signaling to develop compounds that mediate Gs-biased signaling through either inhibition of β-arrestin interaction with the agonist-occupied β2AR (arrestin-biased negative allosteric modulators (NAMs)) or by enhancing coupling of the β2AR to Gs (biased orthosteric agonists). Project 4 will similarly characterize the mechanisms underlying biased signaling of OGR1, develop new biased OGR1 benzodiazepine derivatives with superior ability to bronchodilate, and determine the relative contribution of and mechanisms underlying peripheral benzodiazepine receptor activation by candidate drugs. The four projects will be supported by Core A that will use high through-put screening of small molecule libraries, whole genome, pooled shRNA libraries and virtual screening approaches to identify targets and effectors of bronchodilation. Core B will provide all de-identified human cell and tissue models to study novel mechanisms regulating EC coupling in HASM. Core C will provide administrative support for the program. The strengths of this Program are the common focus on a single theme and the productive working relationship among investigators with the ability to apply cutting edge GPCR biology to key questions in asthma biology and pharmacology.
项目摘要 我们对这个跨学科PPG的更新仍然集中在新的分子机制的主题上, 抑制人气道平滑肌(HASM)收缩并促进支气管扩张, 气道炎症和哮喘。主要假设是G蛋白偶联受体(GPCR) 脱敏和无偏信号传导限制了常规支气管扩张剂的功效, 脱敏机制,促进偏向激动,规避ASM机制 高收缩性/气道高反应性(AHR),或参与新的支气管舒张机制, HASM将为哮喘提供上级治疗。每个项目都通过以下方式解决这一假设:1)优化亲- 松弛信号传导能力的3种不同的GPCR之一,使用的战略植根于尖端的生物物理或 药理学方法;或2)建立介导炎症驱动的AHR的新的细胞内靶点, 增加GPCR促收缩信号传导。 项目1将建立TGF-β 1调节兴奋-收缩(EC)偶联的机制, HASM,从而鉴定与AHR和GPCR介导的增加的GPCR相关的新的治疗靶点。 收缩。项目2将推进最近发现的苦味受体(TAS2R)作为新的 支气管扩张剂阐明TAS2R亚型在HASM中的作用,其调节模式和改善HASM的方法 通过偏向性激动来提高疗效。项目3将描述β 2 AR偏性信号传导的分子基础 为了开发通过抑制β-抑制蛋白相互作用与抑制蛋白相互作用来介导Gs偏置信号传导的化合物, 激动剂占据的β 2AR(抑制蛋白偏向的负向变构调节剂(NAM))或通过增强β 2AR的偶联, β 2 AR至Gs(偏向性正构激动剂)。项目4将类似地描述偏见背后的机制 OGR 1的信号传导,开发具有上级支气管扩张能力的新的偏向OGR 1的苯二氮卓衍生物, 确定外周苯二氮卓受体激活的相对贡献和机制, 候选药物。 这四个项目将得到核心A的支持,核心A将使用高通量筛选小分子 文库、全基因组、混合shRNA文库和虚拟筛选方法来鉴定靶点, 支气管扩张效应器。核心B将提供所有去识别的人类细胞和组织模型,以研究新型 调节HASM中EC偶联的机制。核心C将为该计划提供行政支持。 该计划的优势在于共同关注一个主题,并在以下方面建立富有成效的工作关系: 研究人员有能力将尖端GPCR生物学应用于哮喘生物学和药理学的关键问题。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Reynold Alexander Panettieri其他文献

Reynold Alexander Panettieri的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Reynold Alexander Panettieri', 18)}}的其他基金

New Jersey Alliance for Clinical Translational Science: NJ ACTS
新泽西临床转化科学联盟:NJ ACTS
  • 批准号:
    10260091
  • 财政年份:
    2021
  • 资助金额:
    $ 229.86万
  • 项目类别:
Novel Molecular Mechanisms Promote GPCR-Induced Bronchodilation in Asthma
新型分子机制促进 GPCR 诱导的哮喘支气管扩张
  • 批准号:
    10478318
  • 财政年份:
    2021
  • 资助金额:
    $ 229.86万
  • 项目类别:
Novel Molecular Mechanisms Promote GPCR-Induced Bronchodilation in Asthma
新型分子机制促进 GPCR 诱导的哮喘支气管扩张
  • 批准号:
    10271810
  • 财政年份:
    2021
  • 资助金额:
    $ 229.86万
  • 项目类别:
New Jersey Alliance for Clinical Translational Science: NJ ACTS
新泽西临床转化科学联盟:NJ ACTS
  • 批准号:
    9890029
  • 财政年份:
    2019
  • 资助金额:
    $ 229.86万
  • 项目类别:
New Jersey Alliance for Clinical Translational Science: NJ ACTS
新泽西临床转化科学联盟:NJ ACTS
  • 批准号:
    10582591
  • 财政年份:
    2019
  • 资助金额:
    $ 229.86万
  • 项目类别:
New Jersey Alliance for Clinical Translational Science: NJ ACTS
新泽西临床转化科学联盟:NJ ACTS
  • 批准号:
    10201004
  • 财政年份:
    2019
  • 资助金额:
    $ 229.86万
  • 项目类别:
New Jersey Alliance for Clinical Translational Science: NJ ACTS
新泽西临床转化科学联盟:NJ ACTS
  • 批准号:
    10360219
  • 财政年份:
    2019
  • 资助金额:
    $ 229.86万
  • 项目类别:
New Jersey Alliance for Clinical Translational Science: NJ ACTS
新泽西临床转化科学联盟:NJ ACTS
  • 批准号:
    10360671
  • 财政年份:
    2019
  • 资助金额:
    $ 229.86万
  • 项目类别:
New Jersey Alliance for Clinical Translational Science: NJ ACTS
新泽西临床转化科学联盟:NJ ACTS
  • 批准号:
    10115156
  • 财政年份:
    2019
  • 资助金额:
    $ 229.86万
  • 项目类别:
Project 1 - TGF-beta1 directly modulates excitation-contraction signaling in airway smooth muscle to evoke airway hyperresponsiveness in asthma
项目 1 - TGF-β1 直接调节气道平滑肌中的兴奋收缩信号传导以引起哮喘气道高反应性
  • 批准号:
    10465060
  • 财政年份:
    2013
  • 资助金额:
    $ 229.86万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 229.86万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 229.86万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 229.86万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 229.86万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 229.86万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 229.86万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 229.86万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 229.86万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 229.86万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 229.86万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了